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The hepatitis B virus (HBV) enhancer 1 is a transcriptional element that contributes to the liver-specific regulation of HBV
gene expression. We previously identified a novel protein binding site within the enhancer that contains an 8-bp palindromic
sequence motif. This motif partially overlaps the binding sites for nuclear factor 1 and hepatocyte nuclear factor 3b (HNF3b).
Moreover, we demonstrated that this novel site is recognized by a protein or proteins, tentatively designated as palindrome-
binding factor (PBF), that cooperatively interact with HNF3b. In the present work, we have further examined the biochemical
and functional attributes of PBF. Protein–DNA interaction studies indicate that three thymidine residues located at the 39-end
of the palindromic sequence motif are important for maximal PBF-binding activity. When protein–DNA complexes were
photocrosslinked by exposure to ultraviolet (UV) light, a prominent polypeptide with an apparent molecular mass of 50 kDa
was found to associate with the PBF-binding site. Furthermore, transient transfection studies support the hypothesis that PBF
contributes to enhancer 1 activity by a combinatorial mechanism that involves at least one other cis-acting sequence motif,
the HNF3b-binding site. © 1999 Academic Press
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bINTRODUCTION
The human hepatitis B virus (HBV) predominantly in-
ects the hepatocytes of the liver. The clinical manifes-
ations of chronic HBV infection include severe liver
isease and cirrhosis (Bader, 1995). To compound these
roblems, individuals that are chronically infected with
BV are at high risk for developing primary hepatocel-
ular carcinoma (Beasley and Hwang, 1984). To investi-
ate the molecular basis for the pathogenesis of HBV-
nduced disease, the goal of a considerable amount of
ork has been to characterize the biochemical mecha-
isms that contribute to the hepatotropic nature of this
irus. Studies have addressed this issue by focusing on
iver-specific aspects of HBV gene expression (reviewed
n Kosovsky et al., 1998; Yen, 1993). The HBV genome
ontains four primary translational open reading frames
ORFs) (Fig. 1A), which encode the hepatitis B surface
ntigen [HBsAg (S ORF)], hepatitis B core and e antigens
HBcAg and HBeAg, respectively (C ORF)], viral polymer-
se (P ORF), and X protein (X ORF) (Tiollais et al., 1985).
he regulation of viral transcription is governed by four
romoter elements and two enhancer elements on the
BV genome.
The enhancer 1 element (Fig. 1B) has been shown to
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60lay an important role in the overall regulation of HBV
ene expression. Enhancer 1 facilitates the activation of
he HBV surface antigen (Antonucci and Rutter, 1989;
ulla and Siddiqui, 1988; Hu and Siddiqui, 1991; Su and
ee, 1992), core/pregenomic (Antonucci and Rutter, 1989;
onigwachs et al., 1989; Hu and Siddiqui, 1991; Lopez-
abrera et al., 1990; Su and Yee, 1992; Zhang and
cLachlan, 1994; Zhang et al., 1992), and X (Fukai et al.,
997; Guo et al., 1991; Gustin et al., 1993; Hu and Sid-
iqui, 1991; Zhang et al., 1992) promoter elements. In
ddition, studies of HBV gene expression in transgenic
ice support the conclusion that enhancer 1 activity in
ivo contributes to the liver-specific expression of the
ore/pregenomic promoter (Billet et al., 1995). Work from
number of laboratories further demonstrates that en-
ancer 1 exhibits liver-specific properties (e.g., see An-
onucci and Rutter, 1989; Honigwachs et al., 1989; Jameel
nd Siddiqui, 1986; Shaul et al., 1985). Enhancer 1 activity
s mediated by a complex array of liver-enriched as well
s ubiquitous trans-acting cellular DNA-binding proteins
Fig. 1B) (Kosovsky et al., 1998; Schaller and Fischer,
991; Shaul, 1991; Yen, 1993). Furthermore, enhancer 1
ppears to be regulated by multiple mechanisms that are
ependent on protein–DNA and protein–protein interac-
ions. For example, enhancer 1 activation is facilitated by
xtracellular signaling through a retinoic acid responsive
lement (RARE) (Garcia et al., 1993; Huan et al., 1995;
uan and Siddiqui, 1992; Raney et al., 1997), by cooper-
tive interactions (Dikstein et al., 1990a, 1990b; Garcia et
l., 1993; Kosovsky et al., 1996; Reinhold et al., 1995), and
y trans-activation via the HBV X protein (Doria et al.,
995; Faktor and Shaul, 1990; Maguire et al., 1991; Span-
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61PALINDROMIC SEQUENCE MOTIF WITHIN HBV ENHANCER 1au and Lee, 1988). In addition to activation mecha-
isms, a recent study has shown that enhancer 1 activity
s down-regulated by the tumor suppressor protein p53
Ori et al., 1998).
A number of studies support the conclusion that a
entral region of enhancer 1 located at nucleotides (nt)
080–1165 (HBV subtype adw2), the enhancer core do-
ain (Trujillo et al., 1991), predominantly mediates en-
ancer 1 activity (Dikstein et al., 1990a; Fukai et al., 1997;
arcia et al., 1993; Guo et al., 1991; Huan and Siddiqui,
992; Kosovsky et al., 1996; Ori and Shaul, 1995; Trujillo et
l., 1991). In addition, several protein binding sites lo-
ated 39 of the core domain at nt 1166–1240 appear to
rovide secondary contributions to enhancer 1 activity
Faktor et al., 1990; Garcia et al., 1993; Guo et al., 1991;
aguire et al., 1991; Trujillo et al., 1991). The enhancer
ore domain contains two prominent cis-acting se-
uence motifs that serve as binding sites for liver-en-
iched proteins. Mutational analyses have shown that
FIG. 1. The hepatitis B virus genome and enhancer 1 element. (A) The
, C, P, and X represent the viral genes encoding the surface antigen,
preS1, preS2, Cp, and Xp) and enhancers (Enh 1 and Enh 2) are ind
rotein-binding sites on enhancer 1 are labeled accordingly. Previous
orresponding sites. The gray circle represents the HBV RARE.hese liver-specific motifs are crucial for enhancer 1-me- Hiated transcriptional activation (Chen et al., 1994; Fukai
t al., 1997; Garcia et al., 1993; Guo et al., 1991; Huan and
iddiqui, 1992; Kosovsky et al., 1996; Ori and Shaul,
995). These motifs are recognized by one or more iso-
orms of hepatocyte nuclear factor 3 (HNF3a, b, and/or g)
Chen et al., 1994; Fukai et al., 1997; Kosovsky et al., 1996;
ri and Shaul, 1995) and liver-enriched members of the
ormone nuclear receptor family, which include retinoid
receptor a (RXRa), peroxisome proliferator-activated
eceptor (PPAR), and HNF4 (Fukai et al., 1997; Garcia et
l., 1993; Huan et al., 1995; Huan and Siddiqui, 1992). The
NF3 isoforms are liver-enriched members of the HNF3/
orkhead protein family (Lai et al., 1993; Weigel and
ackle, 1990), which contains proteins that have been
mplicated in the regulation of tissue-specific gene ex-
ression and developmental processes (e.g., Ang and
ossant, 1994; Hellqvist et al., 1996; Lai et al., 1993; Vallet
t al., 1995; Weinstein et al., 1994). Our previous studies
emonstrated that HNF3b is the predominant isoform of
nome is numbered (0–3200 bp) according to the adw2 subtype of HBV.
antigen, polymerase, and X proteins, respectively. The HBV promoters
An, the single polyadenylation site used by all of the HBV RNAs. (B)
ed footprint designations (Patel et al., 1989) are indicated above theviral ge
core/e
icated.
ly definNF3 that interacts with the enhancer core domain (Ko-
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62 KOSOVSKY AND SIDDIQUIovsky et al., 1996). Additionally, we identified a novel
rotein binding site on enhancer 1 that overlaps the NF1-
nd HNF3b-binding sites (Kosovsky et al., 1996). This
ovel site, 59-TACAAGGCCTTTCTAAG-39 (nt 1111–1127),
pans a region containing an 8-bp perfect palindrome
underlined). Given the palindromic nature of this se-
uence motif, the cellular factor or factors that bind to
his site have been designated as palindrome binding
actor (PBF). Moreover, PBF and HNF3b were shown to
ooperatively interact with enhancer 1; therefore, HNF3b
ppears to activate enhancer 1 by cooperatively interact-
ng with at least one other enhancer-binding factor, PBF.
he studies described here further characterize the bio-
hemical properties of PBF and its role in the activation
f enhancer 1.
RESULTS AND DISCUSSION
To further examine the interaction between PBF and
nhancer 1, we analyzed biochemically purified PBF (PBF
ool) using the electrophoretic mobility shift assay
EMSA). DNA competition studies were carried out to
onfirm the specificity of the interaction between PBF
nd enhancer 1 (Fig. 2A). In the absence of competitor
NA, one distinct complex was formed between a pro-
ein or proteins present in the PBF pool and the wild-type
BF oligonucleotide probe (lane 2). When the assay was
arried out in the presence of a 100-fold molar excess of
he unlabeled wild-type PBF oligonucleotide, the protein–
NA complex was markedly reduced (lane 3). However,
n equal amount of nonspecific competitor DNA had no
ffect on the protein–DNA complex (lane 4). Therefore,
he protein–DNA complex results from a specific inter-
ction with the PBF oligonucleotide probe. The specific-
ty of PBF-binding activity is further supported by the DNA
ffinity purification of PBF, which was carried out in the
resence of a high concentration of nonspecific compet-
tor DNA (Kosovsky et al., 1996). We proceeded to carry
ut mutational analyses of the PBF-binding site to deter-
ine the requirements for maximal PBF-binding activity.
oint mutations at the 39-end of the palindromic se-
uence (TTT to GGG) were found to dramatically reduce
BF-binding activity compared with that observed in the
resence of the wild-type PBF probe (Fig. 2B). Additional
oint mutations within the PBF-binding site, which were
nalyzed either independently or in conjunction with the
TT to GGG point mutations, did not further reduce PBF-
inding activity (data not shown). Therefore, the TTT-to-
GG mutations were used for subsequent biochemical
nd functional analyses of the PBF-binding site.
UV crosslinking analysis was then used to identify the
olypeptide or polypeptides that mediate PBF-binding
ctivity. As shown in Fig. 2C, the PBF pool contains a
rotein with an apparent molecular mass of 50 kDa that
xclusively photocrosslinks to the wild-type PBF-binding
ite, yet does not bind appreciably to the mutant PBF
robe. This finding suggests that a 50-kDa protein oresent in rat liver nuclei mediates PBF-binding activity.
n accordance with these results, SDS–PAGE analysis of
he PBF pool revealed the presence of a predominant
urified protein that migrates at an apparent molecular
ass of 50 kDa (Fig. 2D). Additional proteins that were
etected by silver staining exhibited apparent molecular
asses of 43, 60, 70, and 86 kDa. Because the UV
rosslinking method produces a crosslinked product that
s composed of protein and covalently associated oligo-
ucleotide, it is possible that PBF-binding activity is me-
iated by one of the smaller polypeptides of approxi-
ately 43 kDa. This possibility may account for the con-
ribution of the oligonucleotide to the migration of the
rosslinked complex. Furthermore, it is possible that
BF-binding activity is mediated by more than one
olypeptide. In this case, our results would indicate that
nly one polypeptide efficiently crosslinked to the la-
eled probe; therefore, additional studies are necessary
o resolve this important issue.
Because protein–DNA interaction studies demon-
trated that PBF and HNF3b cooperatively interact with
nhancer 1 (Kosovsky et al., 1996), we hypothesized that
NF3b-mediated enhancer activity involves a coopera-
ive interplay between PBF and HNF3b. To address this
ypothesis, we carried out functional analyses of the
BF–HNF3b region in the context of the full-length HBV
nhancer 1 element (Fig. 3). The TTT-to-GGG mutations
escribed above were incorporated into the PBF se-
uence motif within the wild-type and HNF3b mutant
V9Luc; Huan and Siddiqui, 1992) enhancer 1 to generate
he PBF mutant (P9Luc) and the PBF–HNF3b double
utant (P9V9Luc), respectively (Fig. 3A). The reporter
lasmid P9Luc exhibited wild-type levels of enhancer
ctivity, which indicates that mutations within the PBF-
inding site alone do not adversely affect enhancer func-
ion (Fig. 3B). Because PBF exhibited weak binding to the
utant PBF-binding site (Fig. 2B), we hypothesize that
he activity exhibited by P9Luc may be due to wild-type
evels of PBF-binding activity in the presence of HNF3b-
ediated cooperativity. This hypothesis is consistent
ith our preliminary studies, which suggest that cooper-
tive-binding occurs in the presence of the mutated
BF-binding site. Therefore, we suggest that enhancer 1
ctivity is restored to wild-type levels when the PBF
utations are present in conjunction with the wild-type
NF3-binding site. Point mutations within the HNF3b-
inding site alone in V9Luc, which abrogate the interac-
ion between HNF3b and enhancer 1 (Kosovsky et al.,
996), reduced enhancer 1 activity to approximately 41%
f the wild-type level. When mutations were present
ithin both the PBF- and HNF3b-binding sites in
9V9Luc, enhancer activity was further reduced to ap-
roximately 25% of the wild-type level. These results
uggest that the PBF-binding site contributes to en-
ancer 1 activity by a combinatorial mechanism that
nvolves at least one other cis-acting sequence motif, the
verlapping HNF3b-binding site. Moreover, our prelimi-
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63PALINDROMIC SEQUENCE MOTIF WITHIN HBV ENHANCER 1FIG. 2. (A) DNA competition analysis of PBF-binding activity. The EMSA was carried out in the presence of [32P]-labeled PBF oligonucleotide probe. Lane 1, no
rotein; lanes 2–4, 1 ng of the PBF pool incubated in the presence of the following unlabeled competitor DNAs: lane 2, no competitor; lane 3, 100-fold molar excess
f the wild-type PBF oligonucleotide; lane 4, 100-fold molar excess of a nonspecific oligonucleotide (NS). Free probe (F) and bound protein–DNA complexes (B) are
ndicated. (B) Mutational analysis of PBF-binding activity. Protein samples were incubated in the presence of wild-type (lanes 1–3) or mutant (lanes 4–6) [32P]-labeled
BF oligonucleotide probe and the following: lanes 1 and 4, no addition; lanes 2 and 5, 0.67 ng of the PBF pool; and lanes 3 and 6, 1 ng of the PBF pool.
C) UV crosslinking analysis of the PBF pool. Protein samples were incubated in the presence of wild-type (lanes 1 and 2) or mutant (lane 3) [32P]-labeled
BF oligonucleotide probe. Samples were then analyzed by SDS–PAGE and autoradiography. Lane M, [35S]-labeled molecular mass standards in kilodaltons.
amples contained the respective probe and the following: lane 1, no addition; lanes 2 and 3, 1.8 ng of the PBF pool. The black arrowhead indicates the
osition of a crosslinked product with an apparent molecular mass of 50 kDa. The white arrowhead indicates the position of free probe. (D) SDS–PAGE
nalysis of the PBF pool. Proteins were resolved on an SDS–10% polyacrylamide gel and then stained with silver nitrate. The protein sample from the PBF
ool (100 ml) was precipitated in the presence of 4 volumes of acetone for 30 min at 270°C. After centrifugation for 10 min at 13,000 rpm, the protein pellet
as dried and resuspended in SDS-loading buffer before electrophoresis. Lane M, molecular mass standards. Lane PBF, 65 ng of the PBF pool.
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64 KOSOVSKY AND SIDDIQUIary studies suggest that PBF cooperates with NF1 to
urther optimize the binding of nuclear proteins to the
nhancer.
This study further demonstrates that the HBV en-
ancer 1 element is regulated by cooperative interac-
ions between multiple trans-acting cellular proteins. Al-
hough previous work indicated that C/EBP cooperatively
nteracts with enhancer 1, enhancer activity was found to
FIG. 3. Functional analysis of enhancer 1 activity. (A) Reporter plasm
romoter (SV40Ep) and luciferase gene: ENSLuc, wild-type enhancer 1;
nhancer 1 containing point mutations in the HNF3b-binding site; P9V
ites. The thin line and arrows below the PBF–HNF3b region denote the
ransfection assays were performed using the human hepatoma cell
ased on the expression of b-galactosidase. Luciferase activity derived
espective percentage of activity exhibited by the wild-type enhance
nhancerless plasmid containing the SV40Ep upstream of the lucife
xperiments carried out in triplicate.nversely correlate with the concentration of C/EBP (Dik- 1tein et al., 1990b). Moreover, while the protein binding
ites within the HBV RARE–RFX1 region appear to func-
ion in a synergistic manner (Garcia et al., 1993), there
as been no evidence for cooperative interactions be-
ween the trans-acting factors that interact within this
egion. Because HNF3b is a crucial liver-enriched regu-
ator of enhancer 1 (Chen et al., 1994; Fukai et al., 1997;
uo et al., 1991; Huan and Siddiqui, 1992; Kosovsky et al.,
ntain the following enhancer 1 derivatives upstream of the SV40 early
enhancer 1 containing point mutations in the PBF-binding site; V9Luc,
nhancer 1 containing point mutations in the PBF- and HNF3b-binding
lindromic sequence and AGTA direct repeat, respectively. (B) Transient
h-7. Luciferase expression was normalized for transfection efficiency
reporter plasmids containing mutated enhancer 1 is expressed as the
e relevant reporter plasmids are indicated below the graph. SLuc2,
ene. The mean 6 SD values were derived from three independentids co
P9Luc,
9Luc, e
PBF pa
line Hu
from
r 1. Th
rase g996; Ori and Shaul, 1995; Trujillo et al., 1991), we further
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65PALINDROMIC SEQUENCE MOTIF WITHIN HBV ENHANCER 1nvestigated the mechanisms responsible for HNF3b-
ediated enhancer activity. In conjunction with our pre-
ious findings (Kosovsky et al., 1996), transient transfec-
ion studies support the conclusion that HNF3b activates
nhancer 1 by cooperatively interacting with PBF. Al-
hough HNF3 interacts with multiple sites throughout the
BV genome, PBF-facilitated activity appears to be ex-
lusively associated with enhancer 1. Because HNF3a
as been shown to cooperatively interact with NF1 to
egulate the albumin enhancer element (Jackson et al.,
993), PBF may function as a bridging factor to facilitate
cooperative interplay between HNF3b and NF1 on the
BV enhancer 1. Furthermore, our previous functional
nalyses of enhancer 1 deletion mutants demonstrated
hat the NF1–PBF–HNF3b region (nt 1087–1139) inde-
endently exhibits 48% activity compared with the full-
ength enhancer 1 (Trujillo et al., 1991). Therefore, be-
ause the HNF3b-binding site does not exhibit indepen-
ent activity when present as a monomer (Garcia et al.,
993), the activity exhibited by the NF1–PBF–HNF3 re-
ion appears to be mediated by combinatorial effects
etween the overlapping protein-binding sites within this
egion.
MATERIALS AND METHODS
rotein purification
The PBF pool was isolated from rat liver nuclei as
reviously described (Kosovsky et al., 1996). Briefly, rat
iver nuclear extract was fractionated using (NH4)2SO4
recipitation and heparin–Sepharose chromatography.
rotein fractions containing PBF-binding activity were
solated from the heparin–Sepharose pool using two
ounds of DNA oligonucleotide affinity chromatography.
BF-binding activity was then pooled and processed as
escribed. The protein concentration of the PBF pool
as determined by scanning densitometric analysis of a
ilver-stained SDS–polyacrylamide gel using the Molec-
lar Dynamics scanning densitometer.
rotein–DNA interaction assays
The EMSA was carried out essentially as described
Kosovsky et al., 1996). Protein–DNA complexes were
esolved on 6% native polyacrylamide gels, which were
ubsequently dried and exposed to x-ray film at 270°C.
BF-binding activity was analyzed using the following
NA oligonucleotides: (1) wild-type PBF, which spans the
BF-binding site on enhancer 1, 59-CACTTACAAGGCCTTT-
TAAGTAA-39; (2) mutant PBF, 59-CACTTACAAGGCCggg-
TAAGTAA-39 (point mutations are shown in lowercase
etters); and (3) NS (nonspecific competitor), 59-GATC-
GTCAAAGAATTGGTCTTTG-39. Oligonucleotide probes
ere prepared by end-labeling the respective double-
tranded DNAs in the presence of T4 polynucleotide
inase and [g-32P]ATP. Competition analysis was carried
ut in the presence of 100-fold molar excess of unlabeled
ompetitor DNA.For UV crosslinking analysis, the PBF pool was incu-
ated in EMSA reaction buffer in the presence of wild-
ype or mutant PBF [32P]-labeled oligonucleotide probe
or 20 min on ice and then exposed to UV light (l 5 254
m) for 2 min at 4°C. Samples were then supplemented
ith SDS-loading buffer and resolved on an SDS–10%
olyacrylamide gel, which was subsequently dried and
xposed to x-ray film at 270°C. SDS–PAGE and silver
taining were carried out as described (Kosovsky et al.,
996).
ransient transfection assay
To generate reporter plasmids P9Luc and P9V9Luc for
ransient transfection analyses (Fig. 3A), point mutations
ere incorporated into the PBF–HNF3b region within
nhancer 1 using the QuikChange site-directed mu-
agenesis kit according to the manufacturer (Stratagene).
NA sequencing analysis was performed to confirm the
resence of the mutations. Reporter plasmids contained
ild-type or mutant enhancer 1 cloned upstream of the
imian virus 40 early promoter and luciferase gene. Tran-
ient transfection assays were carried out in the human
epatoma cell line Huh-7 essentially as described (Ko-
ovsky et al., 1996). Cell monolayers were transfected
ith 2.0 mg of luciferase reporter plasmid and 2 mg of a
-galactosidase expression plasmid using the calcium
hosphate precipitation method. The cells were incu-
ated for 48 h in the presence of culture medium con-
aining 10% FCS, harvested, and then analyzed for lucif-
rase and b-galactosidase activity.
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